PDGFR LoF Basal calcification. ACCEPTED MANUSCRIPT.pdf (280.95 kB)
Primary brain calcification: an international study reporting novel variants and associated phenotypes.
journal contribution
posted on 2023-06-09, 14:03 authored by Eliana Marisa Ramos, Miryam Carecchio, Roberta Lemos, Joana Ferreira, Andrea Legati, Renee Louise Sears, Sandy Chan Hsu, Celeste Panteghini, Luca Magistrelli, Ettore Salsano, Silvia Esposito, Franco Taroni, Anne-Claire Richard, Christine Tranchant, Mathieu Anheim, Xavier Ayrignac, Cyril Goizet, Marie Vidailhet, David Maltete, David Wallon, Thierry Frebourg, Lylyan Pimentel, Daniel H Geschwind, Olivier Vanakker, Douglas Galasko, Brent L Fogel, A Micheil Innes, Alison Ross, William B Dobyns, Diana AlcantaraDiana Alcantara, Mark O'DriscollMark O'Driscoll, Didier Hannequin, Dominique Campion, The French PBC Study group, João R Oliveira, Barbara Garavaglia, Giovanni Coppola, Gaël NicolasPrimary familial brain calcification (PFBC) is a rare cerebral microvascular calcifying disorder with a wide spectrum of motor, cognitive, and neuropsychiatric symptoms. It is typically inherited as an autosomal-dominant trait with four causative genes identified so far: SLC20A2, PDGFRB, PDGFB, and XPR1. Our study aimed at screening the coding regions of these genes in a series of 177 unrelated probands that fulfilled the diagnostic criteria for primary brain calcification regardless of their family history. Sequence variants were classified as pathogenic, likely pathogenic, or of uncertain significance (VUS), based on the ACMG-AMP recommendations. We identified 45 probands (25.4%) carrying either pathogenic or likely pathogenic variants (n?=?34, 19.2%) or VUS (n?=?11, 6.2%). SLC20A2 provided the highest contribution (16.9%), followed by XPR1 and PDGFB (3.4% each), and PDGFRB (1.7%). A total of 81.5% of carriers were symptomatic and the most recurrent symptoms were parkinsonism, cognitive impairment, and psychiatric disturbances (52.3%, 40.9%, and 38.6% of symptomatic individuals, respectively), with a wide range of age at onset (from childhood to 81 years). While the pathogenic and likely pathogenic variants identified in this study can be used for genetic counseling, the VUS will require additional evidence, such as recurrence in unrelated patients, in order to be classified as pathogenic.
History
Publication status
- Published
File Version
- Accepted version
Journal
European Journal of Human GeneticsISSN
1018-4813Publisher
Nature Publishing GroupExternal DOI
Issue
10Volume
26Page range
1462-1477Department affiliated with
- Global Health and Infection Publications
Research groups affiliated with
- Genome Damage and Stability Centre Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2018-07-03First Open Access (FOA) Date
2018-12-28First Compliant Deposit (FCD) Date
2018-07-02Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC